Heart failure is a clinical syndrome caused by cardiac dysfunction usually secondary to myocardial muscle loss or dysfunction.
It is characterized by either left ventricular hypertrophy or dilation or both.
It leads to neurohormonal and circulatory abnormalities.
Acute heart failure is the rapid onset of or change in the signs and symptoms of heart failure.
It arises as a result of cardiac function deterioration in patients previously diagnosed with heart failure or may also be the first presentation of heart failure.
It is characterized by pulmonary congestion, decreased cardiac output and tissue perfusion.
It is a life-threatening condition that needs immediate medical attention.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Initiation of sacubitril-valsartan combo during hospitalization in Asian patients with heart failure with reduced ejection fraction (HFrEF) appears to lead to a higher incidence of adverse drug reactions (ADRs) and treatment discontinuation when compared with starting the patients on the drug as an outpatient, according to real-world data.
The novel and selective SGLT2 inhibitor luseogliflozin does not seem to produce significant reductions in B‐type natriuretic peptide concentrations in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction (HFpEF) as compared with the alpha‐glucosidase inhibitor voglibose, according to data from the open‐label MUSCAT-HF trial.
In the treatment of patients with type 2 diabetes mellitus, both glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-dependent glucose cotransporter-2 inhibitors (SGLT2-Is) help lower blood pressure, improve glucose control without inducing weight gain, and confer cardio- and renoprotection, as shown in a study.
Patients with heart failure with reduced ejection fraction (HFrEF) who achieve 100 percent guideline-recommended target dose (GRTD) for both angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) and β-blockers have a reduced risk of all-cause mortality and heart failure hospitalization (HHF), a recent study showed.
In the treatment of patients with heart failure with reduced ejection fraction (HFrEF), a comprehensive disease-modifying strategy combining four drugs—namely angiotensin receptor–neprilysin inhibitor (ARNI), β blocker, mineralocorticoid receptor antagonist (MRA), and sodium/glucose cotransporter 2 (SGLT2) inhibitor—yields incremental benefits that contribute to stopping or delaying clinical progression and extending survival, as shown in a study.
While the clinical risk factors for atrial fibrillation (AF) and its associated adverse outcomes are similar across ethnicities in Asia, AF is more common in some ethnic groups than the others, reveal the latest data from the ASIAN-HF* registry.